Tag Archives: Camurus

Lilly Enters Licensing Agreement for Long-Acting Therapies in CVRM; Hims & Hers Reduces Workforce; AstraZeneca Initiates Ph3 Oral PCSK9i Program 

Three cardiometabolic-related news items have been observed: Lilly entered into a licensing agreement with Camurus for long-acting drug delivery technology (view press release); Hims & Hers plans to cut 4% of its workforce (view article); and AstraZeneca initiated its Ph3 AZURE program for AZD0780 (oral PCSK9i) in patients with HeFH (AZURE-HeFH; view CT.gov record), elevated LDL (AZURE-LDL; view CT.gov record), and a CVOT (AZURE-Outcomes; view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.